Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
First Trust NYSE Arca Biotechnology Index Fund (FBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: FBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type ETF | Historic Profit -9.9% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Volume (30-day avg) 21826 | Beta 0.8 | 52 Weeks Range 139.40 - 183.60 | Updated Date 03/28/2025 |
52 Weeks Range 139.40 - 183.60 | Updated Date 03/28/2025 |
Upturn AI SWOT
First Trust NYSE Arca Biotechnology Index Fund
ETF Overview
Overview
The First Trust NYSE Arca Biotechnology Index Fund (FBT) seeks investment results that correspond generally to the price and yield of the NYSE Arca Biotechnology Index. It focuses on the biotechnology sector, allocating assets across companies primarily involved in the research, development, manufacture, and marketing of biotechnological products.
Reputation and Reliability
First Trust is a well-established ETF provider known for its thematic and sector-specific offerings.
Management Expertise
First Trust has a seasoned management team with experience in managing a range of ETFs and other investment products.
Investment Objective
Goal
To track the investment results of the NYSE Arca Biotechnology Index.
Investment Approach and Strategy
Strategy: The ETF employs a replication strategy, aiming to hold all of the securities in the NYSE Arca Biotechnology Index in proportion to their weighting in the index.
Composition The ETF primarily holds stocks of biotechnology companies.
Market Position
Market Share: Information not available to provide accurate market share.
Total Net Assets (AUM): 2340000000
Competitors
Key Competitors
- iShares Biotechnology ETF (IBB)
- SPDR S&P Biotech ETF (XBI)
- ARK Genomic Revolution ETF (ARKG)
Competitive Landscape
The biotechnology ETF market is competitive, with several major players. FBT distinguishes itself with its weighting methodology. IBB is the largest, providing broad exposure, while XBI offers equal-weighting for potentially better diversification. ARKG offers exposure to next-generation DNA sequencing, genetic engineering, and other related technologies.
Financial Performance
Historical Performance: Historical performance data is readily available but not provided here due to constraints.
Benchmark Comparison: Performance typically tracks closely to the NYSE Arca Biotechnology Index but will vary due to expenses and tracking error.
Expense Ratio: 0.0056
Liquidity
Average Trading Volume
The ETF exhibits reasonable liquidity, reflected in a healthy average trading volume.
Bid-Ask Spread
The bid-ask spread is generally tight, implying low trading costs.
Market Dynamics
Market Environment Factors
Factors influencing FBT include FDA approvals, clinical trial outcomes, regulatory changes, and overall market sentiment towards the biotech sector.
Growth Trajectory
Growth depends on advancements in biotechnology, healthcare spending, and demographic trends influencing the demand for biotech products.
Moat and Competitive Advantages
Competitive Edge
FBT benefits from First Trust's established reputation and expertise in managing thematic ETFs. Its focus on biotechnology provides targeted exposure to this growth sector. However, the fund lacks a specific competitive advantage compared to its key competitors. Ultimately, its performance is tied to the performance of its tracked index.
Risk Analysis
Volatility
Biotechnology stocks tend to be volatile due to the nature of drug development and regulatory uncertainties.
Market Risk
The fund is exposed to market risk, regulatory risk (FDA), clinical trial risk, and company-specific risks associated with individual biotechnology companies.
Investor Profile
Ideal Investor Profile
The ideal investor is someone seeking exposure to the biotechnology sector for potential growth, willing to accept higher volatility, and understands the risks associated with the industry.
Market Risk
FBT may be suitable for long-term investors seeking sector-specific growth or active traders aiming to capitalize on short-term trends in the biotech industry.
Summary
The First Trust NYSE Arca Biotechnology Index Fund provides targeted exposure to the biotechnology sector, tracking the NYSE Arca Biotechnology Index. Its performance is closely tied to the success and growth of the companies included in the index. The ETF can be volatile due to the inherent risks associated with biotech. Its relatively low expense ratio may be seen as an advantage. It is suitable for investors seeking sector-specific growth potential.
Similar Companies
- IBB
- XBI
- ARKG
- LABU
- BBC
Sources and Disclaimers
Data Sources:
- First Trust Website
- ETF.com
- Bloomberg
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual circumstances and consultation with a qualified financial advisor. Market share information wasn't available at the time of this response. The market share values of key competitors are assumed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About First Trust NYSE Arca Biotechnology Index Fund
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of 30 leading biotechnology companies.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.